JPWO2019126401A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019126401A5 JPWO2019126401A5 JP2020533728A JP2020533728A JPWO2019126401A5 JP WO2019126401 A5 JPWO2019126401 A5 JP WO2019126401A5 JP 2020533728 A JP2020533728 A JP 2020533728A JP 2020533728 A JP2020533728 A JP 2020533728A JP WO2019126401 A5 JPWO2019126401 A5 JP WO2019126401A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- isolated antibody
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
関連する実施形態において、本開示は、Ｗｎｔシグナリングの増加または強化に関連する疾患または障害を有する対象を治療するための方法であって、対象に、本明細書で開示されている、Ｗｎｔシグナリング経路の阻害物質である単離抗体またはその抗原結合フラグメントを含む医薬組成物の有効量を投与することを含む、方法を提供する。ある特定の実施形態において、疾患または障害は、腫瘍及び癌、変性性障害、線維症、心不全、冠動脈疾患、異所性骨化、骨粗鬆症、及び先天性高骨量障害からなる群より選択される。
特定の実施形態では、例えば、以下が提供される：
（項目１）
１つ以上のＬＲＰ５またはＬＲＰ６受容体に結合する単離抗体またはその抗原結合フラグメントであって、下記を含む配列：
（ｉ）表１Ａのいずれかの抗体について記載されたＣＤＲＨ１、ＣＤＲＨ２、及びＣＤＲＨ３配列、
（ｉｉ）表１Ａのいずれかの抗体について記載されたＣＤＲＬ１、ＣＤＲＬ２、及びＣＤＲＬ３配列、ならびに／または
（ｉｉｉ）表２のいずれかの抗体について記載されたＣＤＲＨ１、ＣＤＲＨ２、ＣＤＲＨ３、ＣＤＲＬ１、ＣＤＲＬ２、及びＣＤＲＬ３配列、を含む、単離抗体またはその抗原結合フラグメント、
あるいは、１つ以上のアミノ酸修飾を含む前記抗体のバリアントまたはその抗原結合フラグメントであって、前記ＣＤＲ配列中に８つ未満のアミノ酸置換を含む、前記抗体のバリアントまたはその抗原結合フラグメント。
（項目２）
配列番号１～２４のいずれかに記載されたアミノ酸配列に対し少なくとも９０％の同一性を有するアミノ酸配列を含む重鎖可変領域を含む、項目１に記載の単離抗体またはその抗原結合フラグメント。
（項目３）
配列番号１～２４のいずれかに記載されたアミノ酸配列を含む重鎖可変領域を含む、項目２に記載の単離抗体またはその抗原結合フラグメント。
（項目４）
前記抗体またはその抗原結合フラグメントがヒト化されている、項目１～３のいずれかに記載の単離抗体またはその抗原結合フラグメント。
（項目５）
前記抗体またはその抗原結合フラグメントが、１本鎖抗体、ｓｃＦｖ、ヒンジ領域を欠いた１価抗体、ＶＨＨもしくはｓｄＡｂ、またはミニボディである、項目１～５のいずれかに記載の単離抗体またはその抗原結合フラグメント。
（項目６）
前記抗体またはその抗原結合フラグメントがＶＨＨ ＶＨＨまたはｓｄＡｂである、項目５に記載の単離抗体またはその抗原結合フラグメント。
（項目７）
前記抗体またはその抗原結合フラグメントがＦａｂまたはＦａｂ’フラグメントである、項目１に記載の単離抗体またはその抗原結合フラグメント。
（項目８）
前記抗体またはその抗原結合フラグメントが融合タンパク質である、項目１～７のいずれかに記載の単離抗体またはその抗原結合フラグメント。
（項目９）
前記抗体またはその抗原結合フラグメントが、１つ以上のフリズルド（Ｆｚｄ）受容体に結合するポリペプチド配列と融合している、項目８に記載の単離抗体またはその抗原結合フラグメント。
（項目１０）
１つ以上のＦｚｄ受容体に結合する前記ポリペプチド配列が、１つ以上のＦｚｄ受容体に結合する抗体またはその抗原結合フラグメントである、項目９に記載の単離抗体またはその抗原結合フラグメント。
（項目１１）
前記抗体またはその抗原結合フラグメントがＬＲＰ５に結合する、項目１～１０のいずれかに記載の単離抗体またはその抗原結合フラグメント。
（項目１２）
前記抗体またはその抗原結合フラグメントがＬＲＰ６に結合する、項目１１に記載の単離抗体またはその抗原結合フラグメント。
（項目１３）
前記抗体またはその抗原結合フラグメントがＬＲＰ５及びＬＲＰ６に結合する、項目１２に記載の単離抗体またはその抗原結合フラグメント。
（項目１４）
ヒトＬＲＰ５またはＬＲＰ６との結合において項目１～１３のいずれかに記載の抗体と競合する、単離抗体またはその抗原結合フラグメント。
（項目１５）
前記ＬＲＰ５またはＬＲＰ６に５０μＭ以下のＫＤで結合する、項目１～１４のいずれかに記載の単離抗体またはその抗原結合フラグメント。
（項目１６）
細胞内の、任意選択で哺乳類細胞内のＷｎｔシグナリング経路を調節する、項目１～１５のいずれかに記載の単離抗体またはその抗原結合フラグメント。
（項目１７）
前記細胞内の前記Ｗｎｔシグナリング経路を介してシグナリングを増加させる、項目１６に記載の単離抗体またはその抗原結合フラグメント。
（項目１８）
前記細胞内の前記Ｗｎｔシグナリング経路を介してシグナリングを減少させる、項目１６に記載の単離抗体またはその抗原結合フラグメント。
（項目１９）
前記Ｗｎｔシグナリング経路がカノニカルＷｎｔシグナリング経路である、項目１６～１８のいずれかに記載の単離抗体またはその抗原結合フラグメント。
（項目２０）
前記Ｗｎｔシグナリング経路が非カノニカルＷｎｔシグナリング経路である、項目１６～１８のいずれかに記載の単離抗体またはその抗原結合フラグメント。
（項目２１）
項目１～２０のいずれかに記載の単離抗体またはその抗原結合フラグメントをコードする、単離ポリヌクレオチド。
（項目２２）
項目２２に記載の単離ポリヌクレオチドを含む、発現ベクター。
（項目２３）
項目２２に記載の発現ベクターを含む、単離宿主細胞。
（項目２４）
生理的に許容される賦形剤、希釈剤、または担体と、項目１～２０または３３のいずれかに記載の単離抗体またはその抗原結合フラグメントの治療有効量とを含む、医薬組成物。
（項目２５）
細胞内のＷｎｔシグナリング経路を刺激するための方法であって、前記細胞を、項目１７に記載の単離抗体またはその抗原結合フラグメントに接触させることを含む、方法。
（項目２６）
前記抗体またはその抗原結合フラグメントが、１つ以上のフリズルド（Ｆｚｄ）受容体に結合するポリペプチド配列を含む融合タンパク質である、項目２４に記載の方法。
（項目２７）
細胞内のＷｎｔシグナリング経路を阻害するための方法であって、前記細胞を、項目１８に記載の単離抗体またはその抗原結合フラグメントに接触させることを含む、方法。
（項目２８）
Ｗｎｔシグナリング低減に関連する疾患または障害を有する対象を治療するための方法であって、前記対象に、項目２４に記載の医薬組成物の有効量を投与することを含み、前記単離抗体またはその抗原結合フラグメントがＷｎｔシグナリング経路のアゴニストである、方法。
（項目２９）
前記疾患または障害が、骨折、疲労骨折、脊椎圧迫骨折、変形性関節症、骨粗鬆症、骨粗鬆症性骨折、癒合不全骨折、癒合遅延骨折、脊椎固定、脊椎手術のための術前最適化、骨壊死、移植または整形外科デバイスの骨結合、骨形成不全症、骨移植、腱修復、腱－骨結合、歯の成長及び再生、顎顔面手術、歯科インプラント、歯周病、顎顔面再構築、顎、臀部、または大腿骨頭の骨壊死、無血管性壊死、脱毛症、難聴、前庭機能低下、黄斑変性、加齢性黄斑変性（ＡＭＤ）、硝子体網膜症、網膜症、糖尿病性網膜症、網膜変性疾患、フックスジストロフィー、角膜疾患、卒中、外傷性脳損傷、アルツハイマー病、多発性硬化症、筋ジストロフィー、サルコペニア及びカヘキシーにおける筋萎縮、血液脳関門（ＢＢＢ）に影響を及ぼす疾患、脊髄損傷、脊髄疾患、口腔粘膜炎、短腸症候群、炎症性腸疾患（ＩＢＤ）、メタボリックシンドローム、糖尿病、脂質異常症、膵炎、膵外分泌機能不全、創傷治癒、糖尿病性足部潰瘍、褥瘡、静脈性下腿潰瘍、表皮水疱症、皮膚形成不全、心筋梗塞、冠動脈疾患、心不全、造血細胞障害、免疫不全、移植片対宿主病、急性腎損傷、慢性腎疾患、慢性閉塞性肺疾患（ＣＯＰＤ）、特発性肺線維症、あらゆる原因の急性肝不全、薬物誘発性急性肝不全、アルコール性肝疾患、あらゆる原因の慢性肝不全、肝硬変、あらゆる原因の肝線維症、門脈圧亢進症、あらゆる原因の慢性肝不全、非アルコール性脂肪性肝炎（ＮＡＳＨ）、非アルコール性脂肪性肝疾患（ＮＡＦＬＤ）（脂肪肝）、アルコール性肝炎、Ｃ型肝炎ウイルス誘発性肝疾患（ＨＣＶ）、Ｂ型肝炎ウイルス誘発性肝疾患（ＨＢＶ）、その他のウイルス性肝炎（例えば、Ａ型肝炎ウイルス誘発性肝疾患（ＨＡＶ）及びＤ型肝炎ウイルス誘発性肝疾患（ＨＤＶ））、原発性胆汁性肝硬変、自己免疫性肝炎、肝臓手術、肝損傷、肝移植、肝臓の手術及び移植における「過小グラフト（ｓｍａｌｌ ｆｏｒ ｓｉｚｅ）」症候群、先天性肝疾患及び肝障害、遺伝性疾患、変性、加齢、薬物、または損傷に起因するその他の任意の肝障害または検出からなる群より選択される、項目２８に記載の方法。
（項目３０）
Ｗｎｔシグナリング増加または強化に関連する疾患または障害を有する対象を治療するための方法であって、前記対象に、項目２４に記載の医薬組成物の有効量を投与することを含み、前記単離抗体またはその抗原結合フラグメントがＷｎｔシグナリング経路の阻害物質である、方法。
（項目３１）
前記疾患または障害が、腫瘍及び癌、変性性障害、任意の臓器または組織の線維症、心不全、冠動脈疾患、異所性骨化、骨粗鬆症、及び先天性高骨量障害からなる群より選択される、項目２９に記載の方法。
（項目３２）
ＬＲＰ６受容体に結合する単離抗体またはその抗原結合フラグメントであって、前記ＬＲＰ６受容体のＥ３ β－プロペラ領域、またはＬＲＰ５受容体の対応領域に結合する、単離抗体またはその抗原結合フラグメント。
（項目３３）
ＬＲＰ６受容体に結合する単離抗体またはその抗原結合フラグメントであって、アミノ酸残基６３７～８７８を含むまたはそれからなる前記ＬＲＰ６受容体の領域内の１つ以上のエピトープ、またはＬＲＰ５受容体の対応領域に結合する、単離抗体またはその抗原結合フラグメント。
（項目３４）
１つ以上のＬＲＰ受容体に結合する単離抗体またはその抗原結合フラグメントであって、表３に示されるいずれかのアミノ酸残基のセットにて、５オングストローム未満の距離で前記ＬＲＰ受容体に接触する、単離抗体またはその抗原結合フラグメント。
In a related embodiment, the present disclosure is a method for treating a subject having a disease or disorder associated with an increase or enhancement of Wnt signaling, the Wnt signaling pathway disclosed herein to the subject. Provided is a method comprising administering an effective amount of a pharmaceutical composition comprising an isolated antibody or an antigen-binding fragment thereof which is an inhibitor of the above. In certain embodiments, the disease or disorder is selected from the group consisting of tumors and cancers, degenerative disorders, fibrosis, heart failure, coronary artery disease, ectopic ossification, osteoporosis, and congenital high bone mass disorders. ..
In certain embodiments, for example, the following are provided:
(Item 1)
An isolated antibody or antigen-binding fragment thereof that binds to one or more LRP5 or LRP6 receptors, comprising the following sequences:
(I) CDRH1, CDRH2, and CDRH3 sequences described for any of the antibodies in Table 1A.
(Ii) The CDRL1, CDRL2, and CDRL3 sequences described for any of the antibodies in Table 1A, and / or
(Iii) An isolated antibody or antigen-binding fragment thereof comprising the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences described for any of the antibodies in Table 2.
Alternatively, a variant of the antibody or an antigen-binding fragment thereof, the variant of the antibody or an antigen-binding fragment thereof, comprising one or more amino acid modifications and comprising less than eight amino acid substitutions in the CDR sequence.
(Item 2)
The isolated antibody or antigen-binding fragment thereof according to item 1, which comprises a heavy chain variable region containing an amino acid sequence having at least 90% identity with respect to the amino acid sequence set forth in any of SEQ ID NOs: 1 to 24.
(Item 3)
The isolated antibody or antigen-binding fragment thereof according to item 2, which comprises a heavy chain variable region comprising the amino acid sequence set forth in any of SEQ ID NOs: 1 to 24.
(Item 4)
The isolated antibody or antigen-binding fragment thereof according to any one of Items 1 to 3, wherein the antibody or antigen-binding fragment thereof is humanized.
(Item 5)
Item 6. The isolated antibody according to any one of Items 1 to 5, wherein the antibody or an antigen-binding fragment thereof is a single-chain antibody, scFv, a monovalent antibody lacking a hinge region, VHH or sdAb, or a minibody. Antigen binding fragment.
(Item 6)
Item 5. The isolated antibody or antigen-binding fragment thereof according to item 5, wherein the antibody or antigen-binding fragment thereof is VHH VHH or sdAb.
(Item 7)
The isolated antibody or antigen-binding fragment thereof according to item 1, wherein the antibody or antigen-binding fragment thereof is a Fab or Fab'fragment.
(Item 8)
The isolated antibody or antigen-binding fragment thereof according to any one of Items 1 to 7, wherein the antibody or antigen-binding fragment thereof is a fusion protein.
(Item 9)
Item 8. The isolated antibody or antigen-binding fragment thereof according to item 8, wherein the antibody or antigen-binding fragment thereof is fused with a polypeptide sequence that binds to one or more frizzled (Fzd) receptors.
(Item 10)
Item 9. The isolated antibody or antigen-binding fragment thereof according to item 9, wherein the polypeptide sequence that binds to one or more Fzd receptors is an antibody that binds to one or more Fzd receptors or an antigen-binding fragment thereof.
(Item 11)
The isolated antibody or antigen-binding fragment thereof according to any one of Items 1 to 10, wherein the antibody or an antigen-binding fragment thereof binds to LRP5.
(Item 12)
The isolated antibody or antigen-binding fragment thereof according to item 11, wherein the antibody or an antigen-binding fragment thereof binds to LRP6.
(Item 13)
Item 12. The isolated antibody or antigen-binding fragment thereof according to item 12, wherein the antibody or antigen-binding fragment thereof binds to LRP5 and LRP6.
(Item 14)
An isolated antibody or antigen-binding fragment thereof that competes with the antibody according to any one of items 1 to 13 in binding to human LRP5 or LRP6.
(Item 15)
The isolated antibody or antigen-binding fragment thereof according to any one of Items 1 to 14, which binds to LRP5 or LRP6 with a KD of 50 μM or less.
(Item 16)
The isolated antibody or antigen-binding fragment thereof according to any one of items 1 to 15, which regulates the Wnt signaling pathway in the intracellular, optionally in mammalian cells.
(Item 17)
Item 16. The isolated antibody or antigen-binding fragment thereof according to item 16, which increases signaling through the Wnt signaling pathway in the cell.
(Item 18)
16. The isolated antibody or antigen-binding fragment thereof according to item 16, which reduces signaling through the Wnt signaling pathway in the cell.
(Item 19)
The isolated antibody or antigen-binding fragment thereof according to any one of items 16 to 18, wherein the Wnt signaling pathway is a canonical Wnt signaling pathway.
(Item 20)
The isolated antibody or antigen-binding fragment thereof according to any one of items 16 to 18, wherein the Wnt signaling pathway is a non-canonical Wnt signaling pathway.
(Item 21)
An isolated polynucleotide encoding the isolated antibody according to any one of items 1 to 20 or an antigen-binding fragment thereof.
(Item 22)
An expression vector comprising the isolated polynucleotide according to item 22.
(Item 23)
An isolated host cell comprising the expression vector according to item 22.
(Item 24)
A pharmaceutical composition comprising a physiologically acceptable excipient, diluent, or carrier and a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof according to any one of items 1-20 or 33.
(Item 25)
A method for stimulating an intracellular Wnt signaling pathway, comprising contacting the cell with an isolated antibody or antigen-binding fragment thereof according to item 17.
(Item 26)
24. The method of item 24, wherein the antibody or antigen binding fragment thereof is a fusion protein comprising a polypeptide sequence that binds to one or more Frizzled (Fzd) receptors.
(Item 27)
A method for inhibiting the intracellular Wnt signaling pathway, comprising contacting the cell with an isolated antibody or antigen-binding fragment thereof according to item 18.
(Item 28)
A method for treating a subject having a disease or disorder associated with Wnt signaling reduction, comprising administering to the subject an effective amount of the pharmaceutical composition according to item 24, the isolated antibody or the isolated antibody thereof. A method in which the antigen binding fragment is an agonist of the Wnt signaling pathway.
(Item 29)
The diseases or disorders include fractures, fatigue fractures, spinal compression fractures, osteoarthritis, osteoporosis, osteoporotic fractures, incomplete fusion fractures, delayed fusion fractures, spinal fusion, preoperative optimization for spinal surgery, osteonecrosis, Bone connection of implantable or orthopedic devices, osteodysplasia, bone transplantation, tendon repair, tendon-bone connection, tooth growth and regeneration, maxillofacial surgery, dental implants, periodontal disease, maxillofacial reconstruction, jaw, buttocks , Or femoral head osteonecrosis, avascular necrosis, alopecia, hearing loss, vestibular dysfunction, yellow spot degeneration, age-related yellow spot degeneration (AMD), vitreous retinopathy, retinopathy, diabetic retinopathy, retinal degenerative disease , Fuchs dystrophy, corneal disease, stroke, traumatic brain injury, Alzheimer's disease, multiple sclerosis, muscular dystrophy, muscle atrophy in sarcopenia and cahexy, diseases affecting the blood-brain barrier (BBB), spinal cord injury, spinal cord disease, oral cavity Mucositis, short bowel syndrome, inflammatory bowel disease (IBD), metabolic syndrome, diabetes, dyslipidemia, pancreatitis, pancreatic exocrine dysfunction, wound healing, diabetic foot ulcer, decubitus, venous lower leg ulcer, epidermal vesicular disease , Skin dysplasia, myocardial infarction, coronary artery disease, heart failure, hematopoietic cell disorder, immunodeficiency, transplant-to-host disease, acute renal injury, chronic renal disease, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, all Causes of acute liver failure, drug-induced acute liver failure, alcoholic liver disease, chronic liver failure of all causes, liver cirrhosis, liver fibrosis of all causes, hypertonic hypertension, chronic liver failure of all causes, non-alcoholic Fatty hepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) (lipohepatitis), alcoholic hepatitis, hepatitis C virus-induced liver disease (HCV), hepatitis B virus-induced liver disease (HBV), Other viral hepatitis (eg, hepatitis A virus-induced liver disease (HAV) and hepatitis D virus-induced liver disease (HDV)), primary biliary cirrhosis, autoimmune hepatitis, liver surgery, liver injury, "Small for size" syndrome in liver transplantation, liver surgery and transplantation, congenital liver disease and liver damage, hereditary disease, degeneration, aging, drugs, or any other liver damage due to injury 28. The method of item 28, selected from the group consisting of detections.
(Item 30)
A method for treating a subject having a disease or disorder associated with increased or enhanced Wnt signaling, comprising administering to the subject an effective amount of the pharmaceutical composition according to item 24, said isolated antibody. Or a method in which the antigen binding fragment is an inhibitor of the Wnt signaling pathway.
(Item 31)
The disease or disorder is selected from the group consisting of tumors and cancers, degenerative disorders, fibrosis of any organ or tissue, heart failure, coronary artery disease, ectopic ossification, osteoporosis, and congenital high bone mass disorders. , Item 29.
(Item 32)
An isolated antibody or antigen-binding fragment thereof that binds to the LRP6 receptor and that binds to the E3 β-propeller region of the LRP6 receptor or the corresponding region of the LRP5 receptor.
(Item 33)
An isolated antibody that binds to the LRP6 receptor or an antigen-binding fragment thereof, the one or more epitopes within the region of the LRP6 receptor comprising or consisting of amino acid residues 637-878, or the corresponding region of the LRP5 receptor. An isolated antibody or antigen-binding fragment thereof that binds to.
(Item 34)
An isolated antibody that binds to one or more LRP receptors or an antigen-binding fragment thereof that contacts the LRP receptor at a distance of less than 5 angstroms with any set of amino acid residues shown in Table 3. An isolated antibody or antigen-binding fragment thereof.
Claims (36)
（ｉ）表１Ａに記載された配列番号１０７のＣＤＲＨ１配列、配列番号２０３のＣＤＲＨ２配列、及び配列番号４５２のＣＤＲＨ３配列、 (I) the CDRH1 sequence of SEQ ID NO: 107, the CDRH2 sequence of SEQ ID NO: 203, and the CDRH3 sequence of SEQ ID NO: 452, which are shown in Table 1A.
を含む、単離抗体またはその抗原結合フラグメント、An isolated antibody or antigen-binding fragment thereof, including
あるいは、１つ以上のアミノ酸修飾を含む前記抗体のバリアントまたはその抗原結合フラグメントであって、前記ＣＤＲ配列中に８つ未満のアミノ酸置換を含む、前記抗体のバリアントまたはその抗原結合フラグメント。 Alternatively, a variant of the antibody or an antigen-binding fragment thereof, the variant of the antibody or an antigen-binding fragment thereof, comprising one or more amino acid modifications and comprising less than eight amino acid substitutions in the CDR sequence.
（ｉ）表１Ａのいずれかの抗体について記載されたＣＤＲＨ１、ＣＤＲＨ２、及びＣＤＲＨ３配列、
（ｉｉ）表１Ａのいずれかの抗体について記載されたＣＤＲＬ１、ＣＤＲＬ２、及びＣＤＲＬ３配列、ならびに／または
（ｉｉｉ）表２のいずれかの抗体について記載されたＣＤＲＨ１、ＣＤＲＨ２、ＣＤＲＨ３、ＣＤＲＬ１、ＣＤＲＬ２、及びＣＤＲＬ３配列、を含む、単離抗体またはその抗原結合フラグメント、
あるいは、１つ以上のアミノ酸修飾を含む前記抗体のバリアントまたはその抗原結合フラグメントであって、前記ＣＤＲ配列中に８つ未満のアミノ酸置換を含む、前記抗体のバリアントまたはその抗原結合フラグメント。 An isolated antibody or antigen-binding fragment thereof that binds to one or more LRP5 or LRP6 receptors, comprising the following sequences:
(I) CDRH1, CDRH2, and CDRH3 sequences described for any of the antibodies in Table 1A.
(Ii) the CDRL1, CDRL2, and CDRL3 sequences described for any antibody of Table 1A and / or (iii) the CDRH1, CDRH2, CDRH3, CDRL1, and / or (iii) described for any antibody of Table 2; An isolated antibody or antigen-binding fragment thereof, comprising a CDRL3 sequence,
Alternatively, a variant of the antibody or an antigen-binding fragment thereof, the variant of the antibody or an antigen-binding fragment thereof, comprising one or more amino acid modifications and comprising less than eight amino acid substitutions in the CDR sequence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023116796A JP2023134705A (en) | 2017-12-19 | 2023-07-18 | Anti-lrp5/6 antibodies and methods of use |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607879P | 2017-12-19 | 2017-12-19 | |
| US62/607,879 | 2017-12-19 | ||
| US201862680515P | 2018-06-04 | 2018-06-04 | |
| US62/680,515 | 2018-06-04 | ||
| PCT/US2018/066620 WO2019126401A1 (en) | 2017-12-19 | 2018-12-19 | Anti-lrp5/6 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116796A Division JP2023134705A (en) | 2017-12-19 | 2023-07-18 | Anti-lrp5/6 antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021508683A JP2021508683A (en) | 2021-03-11 |
| JPWO2019126401A5 true JPWO2019126401A5 (en) | 2022-02-07 |
| JP7317016B2 JP7317016B2 (en) | 2023-07-28 |
Family
ID=66992884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533728A Active JP7317016B2 (en) | 2017-12-19 | 2018-12-19 | Anti-LRP5/6 Antibodies and Methods of Use |
| JP2023116796A Pending JP2023134705A (en) | 2017-12-19 | 2023-07-18 | Anti-lrp5/6 antibodies and methods of use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116796A Pending JP2023134705A (en) | 2017-12-19 | 2023-07-18 | Anti-lrp5/6 antibodies and methods of use |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11746150B2 (en) |
| EP (1) | EP3731867A4 (en) |
| JP (2) | JP7317016B2 (en) |
| CN (1) | CN111699003B (en) |
| AU (1) | AU2018393076A1 (en) |
| CA (1) | CA3085785A1 (en) |
| WO (1) | WO2019126401A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018140821A1 (en) | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| CA3085785A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-lrp5/6 antibodies and methods of use |
| EP3732201A4 (en) * | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | Wnt surrogate molecules and uses thereof |
| JP2022539212A (en) * | 2019-07-02 | 2022-09-07 | スロゼン オペレーティング， インコーポレイテッド | Monospecific anti-Frizzled antibodies and methods of use |
| US20230183336A1 (en) * | 2019-08-14 | 2023-06-15 | Modmab Therapeutics Inc. | Antibodies that bind to lrp5 proteins and methods of use |
| US20240139329A1 (en) * | 2022-10-27 | 2024-05-02 | California Institute Of Technology | Targets for Receptor-Mediated Control of Therapeutic Biodistribution and Efficacy |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DK0698097T3 (en) | 1993-04-29 | 2001-10-08 | Unilever Nv | Production of antibodies or (functionalized) fragments thereof derived from Camelidae heavy chain immunoglobulins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| WO2001074164A1 (en) | 2000-03-31 | 2001-10-11 | The General Hospital Corporation | Methods of modulating hair growth |
| US7713526B2 (en) | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| US7135174B2 (en) | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| CA2965865C (en) * | 2002-07-18 | 2021-10-19 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| ES2897506T3 (en) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identification and modification of antibodies with variant Fc regions and methods of using them |
| US8637506B2 (en) | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| WO2005032574A1 (en) | 2003-10-03 | 2005-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway |
| CA2555820C (en) | 2004-02-19 | 2016-01-19 | Genentech, Inc. | Cdr-repaired antibodies |
| JP5122278B2 (en) | 2004-05-13 | 2013-01-16 | ユニバーシティ オブ バージニア パテント ファウンデーション | Use of lacritin in promoting ocular cell survival |
| US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| US8343922B2 (en) | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| JP4840939B2 (en) | 2004-08-04 | 2011-12-21 | アムジェン インコーポレイテッド | Antibody to DKK-1 |
| DE102004050620A1 (en) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoclonal antibody against Frizzled receptors |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| US7771937B2 (en) * | 2005-05-20 | 2010-08-10 | University Of Washington | Methods for predicting late onset Alzheimer disease in an individual |
| WO2006130076A1 (en) | 2005-05-30 | 2006-12-07 | Astrazeneca Ab | Methods for identifying fzd8 modulators and the use of such modulators for treating osteoarthritis |
| DE102005035568A1 (en) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 as a biomarker for substructures of the human brain |
| CA2635906A1 (en) | 2006-02-07 | 2007-08-16 | Wyeth | Materials and methods for identifying agents that modulate norrin. norrin mimetics, and agents identified thereby |
| CA2654317A1 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| KR101351208B1 (en) | 2006-06-21 | 2014-01-14 | 온코세라피 사이언스 가부시키가이샤 | Tumor-targeting monoclonal antibodies to fzd10 and uses thereof |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| PL2104682T3 (en) | 2007-01-11 | 2017-03-31 | Michael Bacher | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
| US20100199362A1 (en) | 2007-04-26 | 2010-08-05 | President And Fellows Of Harvard College | Wnt ligands involved in blood-brain barrier development and uses therefor |
| CN101951954A (en) | 2007-11-02 | 2011-01-19 | 诺瓦提斯公司 | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
| EP3211011A1 (en) * | 2007-11-16 | 2017-08-30 | Nuvelo, Inc. | Antibodies to lrp6 |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| WO2009126304A1 (en) | 2008-04-11 | 2009-10-15 | Biogen Idec Ma Inc. | Therapeutic combinations of anti-igf-1r antibodies and other compounds |
| WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| CN102239180B (en) | 2008-08-18 | 2014-12-31 | 辉瑞大药厂 | Antibodies to CCR2 |
| EP2334702A2 (en) | 2008-09-10 | 2011-06-22 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
| MX2011003183A (en) | 2008-09-26 | 2011-04-21 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof. |
| GB0819449D0 (en) | 2008-10-23 | 2008-12-03 | Cambridge Display Tech Ltd | Display drivers |
| WO2010054007A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| HUE028647T2 (en) | 2009-02-03 | 2016-12-28 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising said stem cells. |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US20100254979A1 (en) | 2009-03-06 | 2010-10-07 | Cisthera, Incorporated | Humanized PAI-1 Antibodies and Uses Thereof |
| CN102459346B (en) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | The method manufacturing heteromultimers molecule |
| CN103403026B (en) * | 2009-09-25 | 2016-05-11 | 美国政府(由卫生和人类服务部的部长所代表) | HIV-1 neutralizing antibody and uses thereof |
| WO2011043591A2 (en) | 2009-10-06 | 2011-04-14 | Snu R&Db Foundation | Method for differentiation into retinal cells from stem cells |
| EP3112382A1 (en) | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Heterodimer binding proteins and uses thereof |
| CA2787027A1 (en) | 2010-01-13 | 2011-07-21 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Detection of gastrointestinal disorders |
| CA2790200A1 (en) | 2010-02-19 | 2011-08-25 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
| CA2791991A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
| CN102971337B (en) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | FZ combines medicament and application thereof |
| WO2011127164A2 (en) | 2010-04-08 | 2011-10-13 | Fate Therapeutics, Inc. | Pharmaceutical compositions to treat fibrosis |
| US9290573B2 (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
| EP4234698A3 (en) | 2010-05-06 | 2023-11-08 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| MX352929B (en) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain. |
| KR20140035337A (en) | 2011-01-28 | 2014-03-21 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Wnt compositions and methods of use thereof |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| JP5944994B2 (en) | 2011-08-12 | 2016-07-05 | オメロス コーポレーション | Anti-FZD10 monoclonal antibodies and methods for their use |
| WO2013054307A2 (en) | 2011-10-14 | 2013-04-18 | Novartis Ag | Antibodies and methods for wnt pathway-related diseases |
| SG11201401717VA (en) | 2011-11-04 | 2014-05-29 | Novartis Ag | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
| BR112014015018A2 (en) | 2011-12-19 | 2020-10-27 | Synimmune Gmbh | bispecific antibody molecules and their method of production, as well as pharmaceutical composition and nucleic acid molecule |
| AU2013209707A1 (en) | 2012-01-18 | 2014-07-24 | Genentech, Inc. | Anti-LRP5 antibodies and methods of use |
| EP2888279A1 (en) | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
| WO2014059068A1 (en) | 2012-10-11 | 2014-04-17 | The Trustees Of The University Of Pennsylvania | Methods for the treatment and prevention of osteoporosis and bone-related disorders |
| JP6324974B2 (en) * | 2012-10-12 | 2018-05-23 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | Antibody-based reagents that specifically recognize toxic oligomeric forms of tau |
| EP2950885B1 (en) | 2013-02-04 | 2018-11-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
| JP2016509014A (en) | 2013-02-08 | 2016-03-24 | ステムセントリックス， インコーポレイテッド | New multispecific construct |
| WO2014130728A1 (en) | 2013-02-21 | 2014-08-28 | Van Andel Research Institute | Norrin mutant polypeptides, methods of making and uses thereof |
| US20140255403A1 (en) | 2013-03-06 | 2014-09-11 | Hadasit Medical Research Services & Development Ltd. | Oral composition comprising a tnf antagonist and use thereof |
| CA2900955A1 (en) | 2013-03-14 | 2014-10-02 | Oncomed Pharmaceuticals, Inc. | Met-binding agents and uses thereof |
| EA032830B1 (en) | 2013-03-15 | 2019-07-31 | Эмджен Инк. | Human pac1 antibodies and use thereof for treating headache |
| US9850297B2 (en) | 2013-03-15 | 2017-12-26 | Amgen Inc. | Secreted frizzle-related protein 5 (SFRP5) binding proteins |
| AU2014306564B2 (en) | 2013-08-14 | 2019-10-17 | Modmab Therapeutics Corporation | Antibodies against frizzled proteins and methods of use thereof |
| GB2518221A (en) | 2013-09-16 | 2015-03-18 | Sergej Michailovic Kiprijanov | Tetravalent antigen-binding protein molecule |
| MX2016003617A (en) | 2013-09-30 | 2016-07-21 | Chugai Pharmaceutical Co Ltd | Method for producing antigen-binding molecule using modified helper phage. |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| US9629801B2 (en) * | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| IL279606B (en) | 2014-08-08 | 2022-08-01 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| EP3189134A1 (en) | 2014-09-03 | 2017-07-12 | The Brigham and Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| JP6796059B2 (en) | 2014-09-12 | 2020-12-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | WNT signaling agonist molecule |
| BR112017010513A2 (en) | 2014-11-20 | 2018-04-03 | F. Hoffmann-La Roche Ag | Common light chains and methods of use |
| US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2016168607A1 (en) | 2015-04-15 | 2016-10-20 | University Of Tennessee Research Foundation | Compositions and methods of muc13 antibodies for cancer treatment and diagnosis |
| US20160312207A1 (en) | 2015-04-21 | 2016-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling |
| WO2016205566A1 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| WO2016205551A2 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| AU2016341982B2 (en) | 2015-10-21 | 2022-07-07 | Indiana University Research And Technology Corporation | Methods of generating human inner ear sensory epithelia and sensory neurons |
| US10919968B2 (en) | 2016-01-29 | 2021-02-16 | Modmab Therapeutics Corporation | Frizzled5 protein-binding agents |
| BR112018015715A2 (en) | 2016-02-03 | 2019-02-05 | Amgen Inc | bispecific bcma and cd3 t cell coupling antibody constructs |
| EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
| MX2018009581A (en) | 2016-02-06 | 2019-05-06 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof. |
| CA3014659A1 (en) | 2016-03-02 | 2017-09-08 | Frequency Therapeutics, Inc. | Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors |
| JP7023853B2 (en) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | Anti-TREM1 antibody and its usage |
| US20170349659A1 (en) | 2016-06-03 | 2017-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt signaling agonist molecules |
| CA3049661A1 (en) | 2017-01-11 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin (rspo) surrogate molecules |
| WO2018140821A1 (en) | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| EP3630816B1 (en) | 2017-05-31 | 2024-03-20 | Boehringer Ingelheim International GmbH | Polypeptides antagonizing wnt signaling in tumor cells |
| EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | Wnt surrogate molecules and uses thereof |
| CA3085785A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-lrp5/6 antibodies and methods of use |
| CA3085596A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-frizzled antibodies and methods of use |
| SG11202007675VA (en) | 2018-02-14 | 2020-09-29 | Antlera Therapeutics Inc | Multivalent binding molecules activating wnt signaling and uses thereof |
| CN112566940A (en) | 2018-07-05 | 2021-03-26 | 瑟罗泽恩公司 | Multispecific WNT surrogate molecules and uses thereof |
| US20210380678A1 (en) | 2018-07-09 | 2021-12-09 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses |
| WO2020132356A1 (en) | 2018-12-19 | 2020-06-25 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| CA3129155A1 (en) | 2019-02-11 | 2020-08-20 | Surrozen, Inc. | Modulation of wnt signalling in ocular disorders |
| US20220195053A1 (en) | 2019-03-11 | 2022-06-23 | Surrozen Operating Inc. | Modulation of wnt signaling in gastrointestinal disorders |
| WO2020206005A1 (en) | 2019-04-02 | 2020-10-08 | Surrozen, Inc. | Modulation of wnt signaling in auditory disorders |
| US11050604B2 (en) | 2019-07-01 | 2021-06-29 | Rampart Communications, Inc. | Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation |
| JP2022539212A (en) | 2019-07-02 | 2022-09-07 | スロゼン オペレーティング， インコーポレイテッド | Monospecific anti-Frizzled antibodies and methods of use |
| WO2021173726A1 (en) | 2020-02-24 | 2021-09-02 | Surrozen, Inc. | Wnt super agonists |
| KR20230109668A (en) | 2020-11-16 | 2023-07-20 | 서로젠 오퍼레이팅, 인크. | Liver-Specific Wnt Signaling Enhancer Molecules and Uses Thereof |
| CA3210599A1 (en) | 2021-03-10 | 2022-09-15 | Russell FLETCHER | Modulation of wnt signaling in gastrointestinal disorders |
| CA3229303A1 (en) | 2021-09-14 | 2023-03-23 | Russell FLETCHER | Modulation of wnt signalling in pulmonary disorders |
-
2018
- 2018-12-19 CA CA3085785A patent/CA3085785A1/en active Pending
- 2018-12-19 US US16/954,483 patent/US11746150B2/en active Active
- 2018-12-19 JP JP2020533728A patent/JP7317016B2/en active Active
- 2018-12-19 WO PCT/US2018/066620 patent/WO2019126401A1/en unknown
- 2018-12-19 AU AU2018393076A patent/AU2018393076A1/en active Pending
- 2018-12-19 EP EP18891239.8A patent/EP3731867A4/en active Pending
- 2018-12-19 CN CN201880086717.9A patent/CN111699003B/en active Active
-
2023
- 2023-07-11 US US18/350,589 patent/US20240150458A1/en active Pending
- 2023-07-18 JP JP2023116796A patent/JP2023134705A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210230260A1 (en) | Antibodies against the rgm a protein and uses thereof | |
| JP5918275B2 (en) | Treatment of osteoarthritis and pain | |
| JP6066912B2 (en) | DKK1 antibody and method of use thereof | |
| US9133272B2 (en) | Bispecific binding agents | |
| JP4840939B2 (en) | Antibody to DKK-1 | |
| JP2021506297A (en) | Wnt surrogate molecule and its use | |
| JP2010524846A (en) | Anti-sclerostin antibody | |
| JP2020506900A5 (en) | ||
| TW200900079A (en) | Methods of treating ophthalmic diseases | |
| CA2981115C (en) | Anti-dkk-1-anti-rankl bispecific antibody compounds | |
| JP2024001292A (en) | MULTI-SPECIFIC Wnt SURROGATE MOLECULES AND USES THEREOF | |
| JPWO2020022475A5 (en) | ||
| US20090263387A1 (en) | Neutralization of GM-CSF for the Treatment of Heart Failure | |
| JPWO2019126401A5 (en) | ||
| RU2020131241A (en) | Antagonistic antigen-binding proteins | |
| JPWO2019126399A5 (en) | ||
| JP2022040124A (en) | Anti-flt-1 antibodies for treating duchenne muscular dystrophy | |
| JPWO2020010308A5 (en) | ||
| JP2019523764A (en) | ETAR antibodies and pharmaceutical compositions and uses thereof | |
| JPWO2020086406A5 (en) | ||
| JP2019516799A (en) | Pharmaceutical composition comprising anti-RANKL antibody, calcium and vitamin D, suitable for the treatment and / or prevention of treatment-induced side effects such as bone metabolism disorders and hypocalcaemia | |
| WO2023032955A1 (en) | Anti-growth hormone antibody | |
| JPWO2021008519A5 (en) | ||
| JPWO2020243448A5 (en) |